Background Neuroblastoma is an aggressive paediatric malignancy with poor outcomes in high-risk patients despite multimodal therapy. [177Lu]Lu-DOTATATE, targeting somatostatin receptor 2 (SSTR2), is under clinical investigation for neuroblastoma. Terbium-161 (161Tb) shares chemical characteristics and a similar half-life with lutetium-177 (177Lu) but offers advantages through its higher emission of Auger and conversion electrons, which may enhance therapeutic efficacy especially for micrometastases and recurrent disease. This study investigates [161Tb]Tb-DOTATATE as a potential complement for treatment of SSTR2-expressing neuroblastoma. Results DOTATATE was successfully radiolabelled with 161Tb, achieving high radiochemical yield and stability. [161Tb]Tb-DOTATATE demonstrated clear SSTR2-specific binding in vitro, as well as biodistribution and tumour uptake comparable to [177Lu]Lu-DOTATATE in vivo. Treatment with [161Tb]Tb-DOTATATE reduced tumour growth in an activity-dependent manner, and demonstrated stronger early tumour control compared to [177Lu]Lu-DOTATATE at comparable administered activities (**p < 0.01 at day 9). Tumour doubling times were longest in the 6 MBq [161Tb]Tb-DOTATATE group (29 vs. 18 days in controls), while the 3 MBq [161Tb]Tb-DOTATATE group showed similar doubling times to 4 MBq [177Lu]Lu-DOTATATE (21 vs. 22 days). This was also reflected in survival, where 6 MBq [161Tb]Tb-DOTATATE achieved the greatest effect (50% increase in median survival), followed by 4 MBq [161Tb]Tb-DOTATATE (36%), while 3 MBq [161Tb]Tb-DOTATATE and 4 MBq [177Lu]Lu-DOTATATE showed more modest improvements (23%). All treatment regimens were well tolerated, and no signs of treatment-related toxicity were observed. Conclusion [161Tb]Tb-DOTATATE demonstrates favourable targeting properties and activity-dependent therapeutic efficacy in preclinical neuroblastoma models without detectable toxicity. These findings encourage us to explore its potential as a complement to [177Lu]Lu-DOTATATE, particularly for targeting minimal residual disease and micrometastases, and warrant further preclinical and clinical evaluation.

[¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma

期刊论文
出版模式：

开放获取
发表日期：

2026年7月28日

查看全文

Saloni Chopra,
Tianqi Xu,
Hanna Berglund,
Amanda Gustafsson,
Marika Nestor

摘要

Background

Neuroblastoma is an aggressive paediatric malignancy with poor outcomes in high-risk patients despite multimodal therapy. [¹⁷⁷Lu]Lu-DOTATATE, targeting somatostatin receptor 2 (SSTR2), is under clinical investigation for neuroblastoma. Terbium-161 (¹⁶¹Tb) shares chemical characteristics and a similar half-life with lutetium-177 (¹⁷⁷Lu) but offers advantages through its higher emission of Auger and conversion electrons, which may enhance therapeutic efficacy especially for micrometastases and recurrent disease. This study investigates [¹⁶¹Tb]Tb-DOTATATE as a potential complement for treatment of SSTR2-expressing neuroblastoma.

Results

DOTATATE was successfully radiolabelled with ¹⁶¹Tb, achieving high radiochemical yield and stability. [¹⁶¹Tb]Tb-DOTATATE demonstrated clear SSTR2-specific binding in vitro, as well as biodistribution and tumour uptake comparable to [¹⁷⁷Lu]Lu-DOTATATE in vivo. Treatment with [¹⁶¹Tb]Tb-DOTATATE reduced tumour growth in an activity-dependent manner, and demonstrated stronger early tumour control compared to [¹⁷⁷Lu]Lu-DOTATATE at comparable administered activities (**p < 0.01 at day 9). Tumour doubling times were longest in the 6 MBq [¹⁶¹Tb]Tb-DOTATATE group (29 vs. 18 days in controls), while the 3 MBq [¹⁶¹Tb]Tb-DOTATATE group showed similar doubling times to 4 MBq [¹⁷⁷Lu]Lu-DOTATATE (21 vs. 22 days). This was also reflected in survival, where 6 MBq [¹⁶¹Tb]Tb-DOTATATE achieved the greatest effect (50% increase in median survival), followed by 4 MBq [¹⁶¹Tb]Tb-DOTATATE (36%), while 3 MBq [¹⁶¹Tb]Tb-DOTATATE and 4 MBq [¹⁷⁷Lu]Lu-DOTATATE showed more modest improvements (23%). All treatment regimens were well tolerated, and no signs of treatment-related toxicity were observed.

Conclusion

[¹⁶¹Tb]Tb-DOTATATE demonstrates favourable targeting properties and activity-dependent therapeutic efficacy in preclinical neuroblastoma models without detectable toxicity. These findings encourage us to explore its potential as a complement to [¹⁷⁷Lu]Lu-DOTATATE, particularly for targeting minimal residual disease and micrometastases, and warrant further preclinical and clinical evaluation.

[161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma

摘要

[¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma